We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$501M
AUM Growth
-$123M
Cap. Flow
-$8.05M
Cap. Flow %
-1.61%
Top 10 Hldgs %
89.85%
Holding
21
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$8.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$284M 56.71%
6,068,125
– –
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$1.4B
$32.8M 6.54%
1,472,331
– –
NUVB icon
3
Nuvation Bio
NUVB
$2.2B
$25.3M 5.04%
2,541,009
– –
HRMY icon
4
Harmony Biosciences
HRMY
$2.04B
$22.7M 4.53%
592,815
-250,000
-30% -$8.05M
ELEV
5
DELISTED
Elevation Oncology
ELEV
$22.1M 4.4%
2,834,910
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.69B
$19.6M 3.91%
1,025,000
– –
SYRE icon
7
Spyre Therapeutics
SYRE
$8.54B
$13.4M 2.68%
67,646
– –
ACRS icon
8
Aclaris Therapeutics
ACRS
$726M
$11.4M 2.28%
634,455
– –
BMEA icon
9
Biomea Fusion
BMEA
$84.6M
$9.56M 1.91%
798,757
– –
TRML
10
DELISTED
Tourmaline Bio
TRML
$9.26M 1.85%
68,292
– –
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$7.61M 1.52%
1,043,267
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$7.3M 1.46%
1,332,485
– –
SPRB
13
Spruce Biosciences
SPRB
$118M
$7.25M 1.44%
16,073
– –
OKUR
14
OnKure Therapeutics
OKUR
$154M
$6.6M 1.32%
88,608
– –
TECX
15
Tectonic Therapeutic
TECX
$529M
$5.63M 1.12%
84,148
– –
MRKR icon
16
Marker Therapeutics
MRKR
$18.8M
$5.31M 1.06%
314,286
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.31M 0.86%
1,386,338
– –
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.42M 0.48%
387,653
– –
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.31M 0.46%
288,571
– –
ZSAN
20
DELISTED
Zosano Pharma Corporation
ZSAN
$1.96M 0.39%
77,664
– –
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$227K 0.05%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Aisling Capital Management held 21 positions worth $501M, down 20% from $625M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 21-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q3 2021 reduction was Harmony Biosciences, cutting an estimated $8.05M.
  • Aisling Capital Management's ten largest holdings make up 90% of its $501M portfolio in Q3 2021.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q3 2021.
  • Aisling Capital Management's portfolio value fell 20% quarter-over-quarter to $501M.

Based on Aisling Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.